,sex,prior_malignancy,diagnosis,age,standard_chemo,transplant,response_chemo,ldh,wbc_pb,neut_pb,mono_pb,hemoglobin,plt,blasts_bm,alt,ast,albumin,creatinine,karyo_complex,karyo_inv_16,karyo_t_8_21,karyo_t_15_17,karyo_t_9_11,karyo_t_6_9,karyo_inv_3,karyo_t_3q,karyo_mono_5,karyo_mono_7,karyo_mono_17,flt3_itd,npm1,runx1,asxl1,tp53,cebpa_bi,bcor,bcorl1,cbl,cux1,dnmt3a,ezh2,gata2,idh1,idh2,jak2,kit,kras,mpl,nras,phf6,ptpn11,setbp1,sf3b1,srsf2,stag2,tet2,u2af1,wt1,zrsr2,id
0,1,1,AML with myelodysplasia-related changes,63.0,1,0,Refractory,,,,,,,59.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,2797
1,1,0,AML with myelodysplasia-related changes,77.0,1,0,Refractory,,,,,,,32.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,2188
2,1,0,AML with myelodysplasia-related changes,74.0,1,0,Unknown,387.0,29.15,38.6,44.7,7.7,93.0,42.0,27.0,23.0,2.3,1.64,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2758
3,1,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,30.0,1,0,Complete Response,,41.42,,,5.7,14.0,80.0,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2804
4,0,0,AML with mutated NPM1,65.0,1,1,Complete Response,905.0,84.69,11.3,50.0,7.2,150.0,74.0,23.0,32.0,2.6,0.78,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2393
5,0,0,AML with mutated NPM1,52.0,1,0,Complete Response,,22.1,40.2,0.9,8.3,48.0,83.0,21.0,47.0,3.3,0.55,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2292
6,1,0,AML with mutated NPM1,61.0,1,0,Complete Response,1146.0,3.28,12.9,2.0,6.7,21.0,25.0,16.0,42.0,2.9,0.92,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2258
7,0,0,AML with mutated NPM1,56.0,1,1,Complete Response,,58.7,13.0,57.0,9.5,28.0,1.5,67.0,33.0,3.0,1.87,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2522
8,1,1,"Acute myeloid leukaemia, NOS",69.0,1,0,Refractory,,,,,,,94.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,2724
9,0,0,"Acute myeloid leukaemia, NOS",63.0,1,0,Unknown,,9.4,,,,,85.0,,,,,,,,,,,,,,,,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2597
10,1,0,AML with myelodysplasia-related changes,74.0,0,0,,399.0,11.8,24.0,18.0,7.1,107.0,60.0,250.0,160.0,3.2,0.59,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2286
11,0,0,AML with myelodysplasia-related changes,78.0,0,0,,342.0,51.64,35.0,49.0,8.3,50.0,,9.0,15.0,2.9,1.09,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2020
12,1,1,AML with myelodysplasia-related changes,72.0,1,0,Unknown,435.0,20.82,20.6,27.0,6.6,33.0,55.0,32.0,31.0,2.2,1.37,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2554
13,1,0,AML with mutated NPM1,42.0,1,1,Complete Response,945.0,48.03,4.0,7.0,9.5,39.0,81.0,89.0,50.0,3.0,0.94,,,,,,,,,,,,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2285
14,0,0,AML without maturation,27.0,1,1,Refractory,440.0,24.3,1.8,0.9,7.1,53.0,61.0,17.0,33.0,3.5,0.64,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2626
15,0,0,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72.0,1,1,Complete Response,,44.76,,,,,59.3,,,,,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2474
16,1,0,AML with mutated NPM1,60.0,1,0,Complete Response,612.0,70.84,1.0,10.0,4.6,80.0,90.0,30.0,26.0,2.4,1.17,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2366
17,1,0,AML with myelodysplasia-related changes,21.0,1,1,Complete Response,,2.1,,17.0,,,66.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2016
18,1,0,AML with myelodysplasia-related changes,55.0,1,1,Complete Response,,17.99,15.4,20.5,9.6,21.0,60.0,,,,,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2719
19,1,0,"Acute myeloid leukaemia, NOS",71.0,1,0,Complete Response,195.0,2.0,37.6,2.6,11.2,89.0,,21.0,27.0,3.9,0.93,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2165
20,1,0,AML without maturation,67.0,0,0,,,,,,,,82.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,2669
21,1,0,AML with mutated NPM1,48.0,1,0,Unknown,231.0,6.3,84.7,4.4,14.0,330.0,13.0,84.0,28.0,3.9,0.95,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2122
22,0,0,AML with maturation,71.0,1,0,Unknown,,68.85,38.9,1.6,6.8,9.0,25.0,13.0,49.0,2.4,0.68,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2777
23,0,0,AML with mutated NPM1,70.0,1,0,Refractory,592.0,112.3,3.0,0.0,10.9,8.0,97.0,30.0,38.0,2.8,0.92,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2053
24,1,0,Myeloid leukaemia associated with Down syndrome,8.0,1,0,Complete Response,,67.53,8.1,13.5,9.3,40.0,70.0,13.0,25.0,3.2,0.72,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2386
25,0,0,AML with mutated NPM1,71.0,1,0,Complete Response,,1.6,,,,96.0,65.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2362
26,0,0,AML with mutated NPM1,27.0,1,0,Complete Response,,5.1,,1.0,,,69.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,2149
27,0,0,"Acute myeloid leukaemia, NOS",70.0,1,0,Unknown,,7.7,2.0,18.0,8.2,35.0,90.0,24.0,26.0,3.8,0.76,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2140
28,0,1,AML with myelodysplasia-related changes,71.0,1,0,Complete Response,685.0,12.87,17.0,8.0,6.4,11.0,46.0,32.0,39.0,3.3,0.73,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2562
29,0,0,Acute myelomonocytic leukaemia,53.0,1,1,Complete Response,426.0,6.63,30.0,20.0,6.2,38.0,20.0,18.0,23.0,3.3,0.86,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2222
30,1,0,AML with myelodysplasia-related changes,62.0,1,1,Unknown,,16.4,42.0,28.0,12.4,237.0,,37.0,29.0,4.7,1.03,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,2440
31,1,0,AML with mutated NPM1,56.0,0,0,,496.0,8.39,3.5,0.9,8.1,23.0,68.0,22.0,23.0,3.6,1.09,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2800
32,0,0,AML with myelodysplasia-related changes,59.0,1,0,Complete Response,,3.7,,,7.4,51.0,3.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2775
33,1,0,AML with mutated CEBPA,60.0,1,1,Complete Response,267.0,5.18,32.7,0.9,7.1,39.0,35.0,54.0,26.0,2.4,0.75,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,2712
34,1,0,AML with myelodysplasia-related changes,58.0,1,1,Complete Response,,100.2,,,,,57.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2465
35,1,0,unknown,,0,0,,,,,,,,,,,,,,,,,,,,,,,,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2477
36,0,0,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,47.0,1,0,Complete Response,819.0,25.11,13.9,13.1,6.5,9.0,85.0,19.0,37.0,3.3,0.6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2448
37,0,0,Acute myelomonocytic leukaemia,52.0,1,0,Complete Response,,65.58,19.0,21.0,6.5,21.0,,54.0,50.0,2.2,0.84,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2251
38,1,0,"Acute myeloid leukaemia, NOS",58.0,1,0,Refractory,,4.17,,,,,44.6,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2185
39,1,0,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,26.0,1,0,Complete Response,484.0,4.95,15.0,1.0,6.3,105.0,81.0,47.0,44.0,4.4,0.8,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573
40,1,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,46.0,1,0,Refractory,593.0,47.64,21.8,34.5,12.7,42.0,36.0,24.0,16.0,3.1,0.88,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2700
41,1,0,Acute myelomonocytic leukaemia,75.0,1,0,Complete Response,,,,,,,64.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2231
42,1,0,AML with myelodysplasia-related changes,63.0,1,0,Refractory,,1.9,,,,79.0,,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2695
44,0,0,AML with mutated NPM1,23.0,1,1,Complete Response,145.0,29.58,10.7,0.0,8.9,54.0,80.0,17.0,7.0,3.0,0.68,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2755
45,0,0,AML with minimal differentiation,0.0,1,1,Complete Response,8707.0,133.39,5.8,63.1,5.6,28.0,,55.0,179.0,3.2,0.26,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2727
46,1,0,Acute myelomonocytic leukaemia,22.0,1,1,Refractory,1186.0,82.99,0.0,1.8,9.5,95.0,92.0,22.0,35.0,2.5,0.71,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2694
47,0,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31.0,1,1,Complete Response,,123.0,,,,,51.7,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2821
48,1,0,AML with myelodysplasia-related changes,79.0,0,0,,,70.01,,,,27.0,86.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2037
49,1,0,AML with myelodysplasia-related changes,65.0,1,1,Unknown,,19.8,,,,33.0,95.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2073
50,1,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,44.0,1,1,Complete Response,,102.09,,,,23.0,74.8,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2630
51,0,0,AML without maturation,70.0,1,0,Refractory,623.0,27.26,0.0,0.0,9.5,57.0,85.0,30.0,34.0,3.5,0.81,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2620
52,0,0,AML with mutated NPM1,70.0,1,0,Complete Response,,,,,,,25.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2357
53,1,0,AML with myelodysplasia-related changes,53.0,1,0,Refractory,399.0,3.81,15.5,0.9,8.4,23.0,95.0,30.0,24.0,3.3,0.87,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2834
54,1,0,AML with mutated NPM1,59.0,1,0,Complete Response,479.0,4.4,71.4,0.9,8.9,101.0,30.0,77.0,27.0,3.4,1.01,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2441
55,1,0,"Acute myeloid leukaemia, NOS",60.0,1,1,Complete Response,,25.5,2.0,1.0,9.9,48.0,95.0,37.0,32.0,3.2,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2624
56,1,0,"Acute myeloid leukaemia, NOS",74.0,0,0,,,47.5,51.0,2.0,7.8,35.0,19.0,29.0,38.0,3.7,0.86,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,2347
57,0,0,AML with mutated NPM1,61.0,0,0,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2431
58,0,1,Myeloid sarcoma,66.0,1,0,Refractory,,4.33,62.1,9.7,7.7,226.0,13.0,58.0,48.0,2.7,1.1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2076
59,0,0,AML with mutated NPM1,65.0,1,1,Complete Response,506.0,58.86,4.6,85.2,9.6,112.0,70.0,16.0,13.0,2.7,0.87,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2305
60,1,0,Acute monoblastic and monocytic leukaemia ,23.0,1,1,Complete Response,2144.0,98.29,1.8,0.9,8.6,56.0,95.0,68.0,83.0,2.8,0.78,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2660
61,0,0,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,33.0,1,0,Complete Response,,12.75,,,,26.0,,,,,,,,,,,,,,,,,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2318
62,1,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31.0,1,0,Complete Response,434.0,41.35,3.0,21.0,10.2,34.0,80.0,63.0,39.0,3.9,0.91,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2370
63,1,1,AML with mutated NPM1,64.0,1,1,Complete Response,,53.3,13.0,0.0,8.7,39.0,83.0,15.0,45.0,4.0,1.27,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2206
64,0,0,Acute erythroid leukaemia,53.0,1,1,Complete Response,,2.1,22.0,10.0,7.4,38.0,9.0,14.0,40.0,3.3,0.65,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2289
65,0,0,AML with mutated NPM1,63.0,1,1,Refractory,,40.36,,,9.2,135.0,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2654
66,1,0,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,32.0,1,0,Unknown,,7.19,3.6,0.9,6.3,49.0,80.0,31.0,20.0,3.0,0.84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2236
67,1,0,"Acute myeloid leukaemia, NOS",62.0,1,1,Refractory,,44.8,9.0,2.0,7.0,50.0,35.0,83.0,69.0,2.8,0.99,,,,,,,,,,,,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2767
68,0,0,AML with mutated NPM1,45.0,0,0,,,,,,,,69.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2647
69,1,0,AML with myelodysplasia-related changes,50.0,1,0,Refractory,,50.74,1.8,1.7,6.3,14.0,76.0,7.0,10.0,2.2,0.44,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2250
70,0,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31.0,1,0,Complete Response,229.0,13.63,7.0,20.0,7.4,30.0,57.0,,,,1.04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2128
71,1,0,AML with myelodysplasia-related changes,58.0,1,0,Refractory,,2.64,,,,,78.3,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2534
72,0,0,"Acute myeloid leukaemia, NOS",32.0,1,1,Refractory,125.0,1.4,44.0,0.0,9.0,67.0,24.0,10.0,22.0,4.4,0.49,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2121
73,1,1,AML with t(9;11)(p22;q23); MLLT3-MLL,62.0,1,1,Complete Response,,14.66,,,,,93.0,,,,,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2539
74,1,0,AML with mutated NPM1,72.0,1,0,Complete Response,,125.9,,,,,97.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2316
76,1,0,AML with mutated NPM1,53.0,1,1,Complete Response,,64.3,1.0,3.0,8.2,62.0,93.0,15.0,19.0,1.7,1.03,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2007
77,0,1,Therapy-related myeloid neoplasms,68.0,0,0,,,,,,,,74.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2627
78,1,0,AML without maturation,31.0,1,1,Refractory,165.0,17.92,0.9,1.7,8.6,196.0,90.0,13.0,10.0,3.8,0.97,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2693
79,0,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,51.0,1,1,Complete Response,,34.4,,1.0,,,74.0,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2134
80,1,0,AML with mutated CEBPA,69.0,1,0,Complete Response,,7.62,18.1,14.7,9.9,118.0,60.0,19.0,22.0,2.3,0.87,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2435
81,1,1,AML with mutated NPM1,65.0,1,0,Unknown,,,,,,,,,,,,,,,,,,,,,,,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2481
82,1,0,AML with myelodysplasia-related changes,69.0,1,0,Refractory,,1.6,,,,,39.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2183
83,0,0,AML with t(9;11)(p22;q23); MLLT3-MLL,69.0,1,0,Unknown,,137.6,,0.0,,,94.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2176
84,0,0,AML without maturation,71.0,1,1,Complete Response,,4.92,7.7,1.0,9.5,100.0,98.0,44.0,22.0,3.4,0.7,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2696
85,0,0,AML with mutated NPM1,46.0,1,0,Complete Response,550.0,57.23,10.7,14.9,8.4,107.0,80.0,52.0,28.0,2.5,0.77,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2029
86,1,0,AML with mutated CEBPA,61.0,1,1,Complete Response,,4.17,46.0,0.0,8.1,35.0,40.0,30.0,14.0,3.9,0.84,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2633
87,1,0,AML without maturation,65.0,1,0,Complete Response,509.0,5.39,0.0,0.9,7.4,17.0,90.0,19.0,25.0,3.3,0.78,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2516
88,0,1,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,34.0,1,0,Complete Response,191.0,0.5,22.0,14.0,10.7,32.0,96.0,21.0,15.0,4.0,0.58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2360
89,0,0,AML with myelodysplasia-related changes,79.0,1,0,Unknown,483.0,130.45,1.4,1.5,6.2,126.0,90.0,25.0,29.0,2.9,1.02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2711
90,1,0,AML with myelodysplasia-related changes,65.0,1,0,Refractory,,19.99,47.3,12.5,6.2,9.0,30.0,33.0,50.0,2.3,0.77,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2124
91,0,0,AML with mutated NPM1,83.0,0,0,,333.0,44.85,27.3,14.5,6.5,273.0,75.0,19.0,24.0,2.7,0.77,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2672
92,1,0,AML with mutated NPM1,55.0,1,0,Complete Response,,16.11,,,,283.0,37.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2376
93,1,0,AML with myelodysplasia-related changes,70.0,1,0,Refractory,2064.0,72.0,32.0,64.0,9.8,50.0,80.0,36.0,50.0,4.1,2.45,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2710
94,0,0,AML with myelodysplasia-related changes,55.0,1,1,Complete Response,,10.6,6.8,4.0,9.9,83.0,30.0,10.0,11.0,4.3,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2444
95,1,0,AML with mutated NPM1,59.0,1,0,Complete Response,383.0,3.6,29.2,6.6,7.6,35.0,35.0,13.0,25.0,2.9,1.4,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2242
96,0,0,AML with maturation,75.0,1,0,Unknown,216.0,2.37,5.2,11.3,10.5,38.0,70.0,11.0,9.0,3.2,0.88,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2423
97,0,0,AML with myelodysplasia-related changes,79.0,0,0,,,11.5,24.3,0.9,8.3,31.0,65.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2825
98,1,0,AML with mutated NPM1,61.0,1,0,Complete Response,1205.0,152.75,2.0,2.0,10.1,20.0,81.0,85.0,52.0,3.1,0.85,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2397
99,0,0,AML with mutated NPM1,26.0,1,1,Complete Response,,138.2,3.0,2.0,7.6,19.0,89.5,10.0,21.0,3.0,,,,,,,,,,,,,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2811
100,1,0,"Acute myeloid leukaemia, NOS",46.0,1,0,Unknown,,151.6,1.0,19.0,6.2,31.0,92.0,,,2.8,1.13,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2367
101,0,0,AML with mutated NPM1,61.0,1,0,Unknown,360.0,30.54,1.6,0.8,7.1,43.0,93.0,19.0,21.0,2.7,0.78,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2255
102,1,1,Therapy-related myeloid neoplasms,74.0,1,0,Complete Response,162.0,2.0,60.0,,8.8,60.0,17.0,19.0,18.0,4.2,0.64,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2523
103,1,0,Acute myelomonocytic leukaemia,55.0,1,1,Refractory,,16.66,5.3,59.6,6.6,47.0,54.0,463.0,477.0,2.7,1.14,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2075
104,1,1,AML with myelodysplasia-related changes,76.0,1,0,Complete Response,,4.48,8.5,37.1,7.6,104.0,50.0,18.0,16.0,3.7,1.45,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2453
105,1,0,AML without maturation,55.0,1,0,Unknown,,9.4,9.4,1.7,7.1,34.0,91.0,391.0,343.0,2.8,0.74,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2350
106,0,0,"Acute myeloid leukaemia, NOS",83.0,0,0,,,20.1,,,,77.0,85.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2174
107,1,0,AML with mutated CEBPA,47.0,1,0,Complete Response,290.0,18.71,0.0,3.4,10.2,24.0,83.0,23.0,11.0,3.5,0.95,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2538
108,1,1,Myeloid sarcoma,85.0,0,0,,,11.4,55.0,8.0,16.1,141.0,2.0,4.0,8.0,3.7,1.2,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,2568
109,0,0,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,69.0,1,0,Complete Response,,34.36,6.7,5.0,8.6,39.0,90.0,45.0,41.0,3.4,1.09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2467
110,0,0,AML without maturation,45.0,1,0,Complete Response,2504.0,185.9,4.3,25.6,7.4,59.0,85.0,110.0,114.0,3.8,0.8,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2645
111,0,0,"Acute myeloid leukaemia, NOS",62.0,1,0,Refractory,,,,,,,20.3999999999999,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2537
112,1,1,AML with mutated NPM1,56.0,1,1,Complete Response,,31.02,,,,54.0,89.6,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2287
113,1,0,AML with mutated NPM1,66.0,1,0,Complete Response,387.0,28.0,1.0,61.0,7.9,122.0,90.0,19.0,14.0,2.4,1.13,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2326
114,1,1,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,64.0,1,0,Refractory,,8.69,5.3,30.1,7.7,53.0,,10.0,7.0,2.6,1.33,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2306
115,1,0,Acute megakaryoblastic leukaemia,60.0,1,0,Complete Response,,3.1,,,,136.0,13.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2246
116,0,0,AML with myelodysplasia-related changes,68.0,1,1,Complete Response,,6.7,,,8.5,53.0,20.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2705
117,1,0,AML without maturation,61.0,1,1,Complete Response,330.0,84.96,0.0,0.0,6.8,49.0,92.0,35.0,23.0,3.2,0.86,,,,,,,,,,,,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2424
118,0,0,AML without maturation,60.0,1,0,Complete Response,,1.0,,1.4,,,56.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2118
119,1,0,AML with myelodysplasia-related changes,60.0,1,0,Unknown,293.0,0.94,0.8,0.0,7.1,417.0,15.0,46.0,35.0,1.8,0.56,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,2024
120,0,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,52.0,1,0,Complete Response,,28.1,,0.0,,,91.0,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2348
121,1,0,"Acute myeloid leukaemia, NOS",17.0,1,1,Unknown,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2112
122,0,0,AML with mutated NPM1,63.0,1,1,Complete Response,476.0,62.54,4.6,2.3,8.8,30.0,95.0,,,,0.64,,,,,,,,,,,,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2749
123,0,0,AML with mutated NPM1,59.0,1,1,Complete Response,,89.17,,,,,51.5,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2455
124,0,0,AML with mutated NPM1,53.0,1,0,Complete Response,,1.87,50.3,2.7,8.2,40.0,34.0,10.0,11.0,3.3,0.63,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2765
125,1,0,AML with mutated CEBPA,61.0,1,1,Complete Response,1873.0,427.46,0.9,2.2,5.2,34.0,90.0,22.0,43.0,3.1,1.21,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2119
126,0,1,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,53.0,1,0,Complete Response,588.0,5.1,,,,,69.0,,,,,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2312
127,1,0,AML with maturation,75.0,1,0,Refractory,178.0,1.0,36.8,11.2,9.1,28.0,23.0,23.0,16.0,3.4,0.55,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,2531
128,1,0,AML with mutated NPM1,63.0,1,1,Complete Response,,52.1,1.0,0.0,8.5,51.0,92.0,30.0,16.0,3.3,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2681
129,0,0,Myeloid sarcoma,45.0,1,0,Complete Response,,,,,,,,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2709
130,0,0,AML with mutated NPM1,74.0,1,0,Complete Response,645.0,35.91,35.1,44.7,9.4,71.0,60.0,17.0,28.0,2.6,0.79,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2492
131,1,0,AML with t(9;11)(p22;q23); MLLT3-MLL,38.0,1,0,Complete Response,,25.29,,,,,94.0,,,,,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2704
132,0,0,AML with myelodysplasia-related changes,72.0,1,0,Refractory,85.0,1.62,13.3,0.0,9.4,57.0,47.0,15.0,8.0,2.9,0.51,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2673
133,0,0,AML with myelodysplasia-related changes,62.0,1,0,Refractory,183.0,2.18,36.5,5.2,7.2,32.0,18.0,17.0,14.0,3.8,0.78,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2379
134,1,0,AML with myelodysplasia-related changes,73.0,1,1,Complete Response,228.0,2.07,23.5,7.8,11.1,70.0,57.0,15.0,20.0,3.6,0.69,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2826
135,1,0,Acute monoblastic and monocytic leukaemia ,39.0,1,0,Refractory,,21.12,3.5,17.7,10.7,31.0,90.0,19.0,14.0,3.0,0.97,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2484
136,0,0,AML with mutated NPM1,44.0,1,1,Complete Response,705.0,69.84,6.8,22.2,7.4,42.0,75.0,21.0,25.0,2.4,1.25,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2433
137,0,1,AML with mutated NPM1,39.0,1,1,Complete Response,,190.0,,,,,70.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2570
138,0,0,AML with myelodysplasia-related changes,65.0,1,1,Complete Response,561.0,31.66,18.4,28.3,7.4,60.0,,23.0,29.0,3.0,0.78,,,,,,,,,,,,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2150
139,1,0,AML with mutated NPM1,60.0,1,0,Complete Response,536.0,11.93,15.9,8.3,10.6,141.0,30.0,49.0,23.0,3.5,1.22,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2369
140,1,0,AML with mutated NPM1,55.0,1,1,Complete Response,,24.9,7.0,4.0,10.9,54.0,88.5,34.0,36.0,3.3,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2131
1,1,0,AML with myelodysplasia-related changes,77.0,1,0,Refractory,,,,,,,32.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,3016
3,1,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,30.0,1,0,Complete Response,,41.42,,,5.7,14.0,80.0,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3632
4,0,0,AML with mutated NPM1,65.0,1,1,Complete Response,905.0,84.69,11.3,50.0,7.2,150.0,74.0,23.0,32.0,2.6,0.78,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3221
8,1,1,"Acute myeloid leukaemia, NOS",69.0,1,0,Refractory,,,,,,,94.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,3552
9,0,0,"Acute myeloid leukaemia, NOS",63.0,1,0,Unknown,,9.4,,,,,85.0,,,,,,,,,,,,,,,,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,3425
10,1,0,AML with myelodysplasia-related changes,74.0,0,0,,399.0,11.8,24.0,18.0,7.1,107.0,60.0,250.0,160.0,3.2,0.59,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,3114
13,1,0,AML with mutated NPM1,42.0,1,1,Complete Response,945.0,48.03,4.0,7.0,9.5,39.0,81.0,89.0,50.0,3.0,0.94,,,,,,,,,,,,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3113
15,0,0,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72.0,1,1,Complete Response,,44.76,,,,,59.3,,,,,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,3302
18,1,0,AML with myelodysplasia-related changes,55.0,1,1,Complete Response,,17.99,15.4,20.5,9.6,21.0,60.0,,,,,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3547
19,1,0,"Acute myeloid leukaemia, NOS",71.0,1,0,Complete Response,195.0,2.0,37.6,2.6,11.2,89.0,,21.0,27.0,3.9,0.93,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2993
21,1,0,AML with mutated NPM1,48.0,1,0,Unknown,231.0,6.3,84.7,4.4,14.0,330.0,13.0,84.0,28.0,3.9,0.95,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2950
22,0,0,AML with maturation,71.0,1,0,Unknown,,68.85,38.9,1.6,6.8,9.0,25.0,13.0,49.0,2.4,0.68,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3605
27,0,0,"Acute myeloid leukaemia, NOS",70.0,1,0,Unknown,,7.7,2.0,18.0,8.2,35.0,90.0,24.0,26.0,3.8,0.76,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2968
28,0,1,AML with myelodysplasia-related changes,71.0,1,0,Complete Response,685.0,12.87,17.0,8.0,6.4,11.0,46.0,32.0,39.0,3.3,0.73,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3390
29,0,0,Acute myelomonocytic leukaemia,53.0,1,1,Complete Response,426.0,6.63,30.0,20.0,6.2,38.0,20.0,18.0,23.0,3.3,0.86,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3050
30,1,0,AML with myelodysplasia-related changes,62.0,1,1,Unknown,,16.4,42.0,28.0,12.4,237.0,,37.0,29.0,4.7,1.03,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,3268
31,1,0,AML with mutated NPM1,56.0,0,0,,496.0,8.39,3.5,0.9,8.1,23.0,68.0,22.0,23.0,3.6,1.09,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3628
32,0,0,AML with myelodysplasia-related changes,59.0,1,0,Complete Response,,3.7,,,7.4,51.0,3.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,3603
33,1,0,AML with mutated CEBPA,60.0,1,1,Complete Response,267.0,5.18,32.7,0.9,7.1,39.0,35.0,54.0,26.0,2.4,0.75,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,3540
34,1,0,AML with myelodysplasia-related changes,58.0,1,1,Complete Response,,100.2,,,,,57.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3293
35,1,0,unknown,,0,0,,,,,,,,,,,,,,,,,,,,,,,,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3305
38,1,0,"Acute myeloid leukaemia, NOS",58.0,1,0,Refractory,,4.17,,,,,44.6,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3013
41,1,0,Acute myelomonocytic leukaemia,75.0,1,0,Complete Response,,,,,,,64.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3059
42,1,0,AML with myelodysplasia-related changes,63.0,1,0,Refractory,,1.9,,,,79.0,,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3523
44,0,0,AML with mutated NPM1,23.0,1,1,Complete Response,145.0,29.58,10.7,0.0,8.9,54.0,80.0,17.0,7.0,3.0,0.68,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3583
46,1,0,Acute myelomonocytic leukaemia,22.0,1,1,Refractory,1186.0,82.99,0.0,1.8,9.5,95.0,92.0,22.0,35.0,2.5,0.71,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3522
48,1,0,AML with myelodysplasia-related changes,79.0,0,0,,,70.01,,,,27.0,86.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2865
50,1,0,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,44.0,1,1,Complete Response,,102.09,,,,23.0,74.8,,,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3458
52,0,0,AML with mutated NPM1,70.0,1,0,Complete Response,,,,,,,25.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3185
53,1,0,AML with myelodysplasia-related changes,53.0,1,0,Refractory,399.0,3.81,15.5,0.9,8.4,23.0,95.0,30.0,24.0,3.3,0.87,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3662
55,1,0,"Acute myeloid leukaemia, NOS",60.0,1,1,Complete Response,,25.5,2.0,1.0,9.9,48.0,95.0,37.0,32.0,3.2,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3452
58,0,1,Myeloid sarcoma,66.0,1,0,Refractory,,4.33,62.1,9.7,7.7,226.0,13.0,58.0,48.0,2.7,1.1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2904
59,0,0,AML with mutated NPM1,65.0,1,1,Complete Response,506.0,58.86,4.6,85.2,9.6,112.0,70.0,16.0,13.0,2.7,0.87,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3133
64,0,0,Acute erythroid leukaemia,53.0,1,1,Complete Response,,2.1,22.0,10.0,7.4,38.0,9.0,14.0,40.0,3.3,0.65,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3117
65,0,0,AML with mutated NPM1,63.0,1,1,Refractory,,40.36,,,9.2,135.0,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3482
66,1,0,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,32.0,1,0,Unknown,,7.19,3.6,0.9,6.3,49.0,80.0,31.0,20.0,3.0,0.84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3064
68,0,0,AML with mutated NPM1,45.0,0,0,,,,,,,,69.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3475
74,1,0,AML with mutated NPM1,72.0,1,0,Complete Response,,125.9,,,,,97.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,3144
76,1,0,AML with mutated NPM1,53.0,1,1,Complete Response,,64.3,1.0,3.0,8.2,62.0,93.0,15.0,19.0,1.7,1.03,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2835
78,1,0,AML without maturation,31.0,1,1,Refractory,165.0,17.92,0.9,1.7,8.6,196.0,90.0,13.0,10.0,3.8,0.97,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3521
80,1,0,AML with mutated CEBPA,69.0,1,0,Complete Response,,7.62,18.1,14.7,9.9,118.0,60.0,19.0,22.0,2.3,0.87,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3263
85,0,0,AML with mutated NPM1,46.0,1,0,Complete Response,550.0,57.23,10.7,14.9,8.4,107.0,80.0,52.0,28.0,2.5,0.77,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2857
90,1,0,AML with myelodysplasia-related changes,65.0,1,0,Refractory,,19.99,47.3,12.5,6.2,9.0,30.0,33.0,50.0,2.3,0.77,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2952
92,1,0,AML with mutated NPM1,55.0,1,0,Complete Response,,16.11,,,,283.0,37.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3204
93,1,0,AML with myelodysplasia-related changes,70.0,1,0,Refractory,2064.0,72.0,32.0,64.0,9.8,50.0,80.0,36.0,50.0,4.1,2.45,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3538
97,0,0,AML with myelodysplasia-related changes,79.0,0,0,,,11.5,24.3,0.9,8.3,31.0,65.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3653
101,0,0,AML with mutated NPM1,61.0,1,0,Unknown,360.0,30.54,1.6,0.8,7.1,43.0,93.0,19.0,21.0,2.7,0.78,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3083
102,1,1,Therapy-related myeloid neoplasms,74.0,1,0,Complete Response,162.0,2.0,60.0,,8.8,60.0,17.0,19.0,18.0,4.2,0.64,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3351
104,1,1,AML with myelodysplasia-related changes,76.0,1,0,Complete Response,,4.48,8.5,37.1,7.6,104.0,50.0,18.0,16.0,3.7,1.45,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3281
107,1,0,AML with mutated CEBPA,47.0,1,0,Complete Response,290.0,18.71,0.0,3.4,10.2,24.0,83.0,23.0,11.0,3.5,0.95,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3366
108,1,1,Myeloid sarcoma,85.0,0,0,,,11.4,55.0,8.0,16.1,141.0,2.0,4.0,8.0,3.7,1.2,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,3396
111,0,0,"Acute myeloid leukaemia, NOS",62.0,1,0,Refractory,,,,,,,20.3999999999999,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,3365
114,1,1,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,64.0,1,0,Refractory,,8.69,5.3,30.1,7.7,53.0,,10.0,7.0,2.6,1.33,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3134
115,1,0,Acute megakaryoblastic leukaemia,60.0,1,0,Complete Response,,3.1,,,,136.0,13.0,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3074
116,0,0,AML with myelodysplasia-related changes,68.0,1,1,Complete Response,,6.7,,,8.5,53.0,20.0,,,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3533
122,0,0,AML with mutated NPM1,63.0,1,1,Complete Response,476.0,62.54,4.6,2.3,8.8,30.0,95.0,,,,0.64,,,,,,,,,,,,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3577
123,0,0,AML with mutated NPM1,59.0,1,1,Complete Response,,89.17,,,,,51.5,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3283
128,1,0,AML with mutated NPM1,63.0,1,1,Complete Response,,52.1,1.0,0.0,8.5,51.0,92.0,30.0,16.0,3.3,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3509
130,0,0,AML with mutated NPM1,74.0,1,0,Complete Response,645.0,35.91,35.1,44.7,9.4,71.0,60.0,17.0,28.0,2.6,0.79,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3320
131,1,0,AML with t(9;11)(p22;q23); MLLT3-MLL,38.0,1,0,Complete Response,,25.29,,,,,94.0,,,,,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3532
134,1,0,AML with myelodysplasia-related changes,73.0,1,1,Complete Response,228.0,2.07,23.5,7.8,11.1,70.0,57.0,15.0,20.0,3.6,0.69,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,3654
135,1,0,Acute monoblastic and monocytic leukaemia ,39.0,1,0,Refractory,,21.12,3.5,17.7,10.7,31.0,90.0,19.0,14.0,3.0,0.97,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3312
136,0,0,AML with mutated NPM1,44.0,1,1,Complete Response,705.0,69.84,6.8,22.2,7.4,42.0,75.0,21.0,25.0,2.4,1.25,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3261
139,1,0,AML with mutated NPM1,60.0,1,0,Complete Response,536.0,11.93,15.9,8.3,10.6,141.0,30.0,49.0,23.0,3.5,1.22,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3197
140,1,0,AML with mutated NPM1,55.0,1,1,Complete Response,,24.9,7.0,4.0,10.9,54.0,88.5,34.0,36.0,3.3,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2959
